$1.04
+0.01 (+0.97%)
Open$0.96
Previous Close$1.03
Day High$1.09
Day Low$0.95
52W High$3.15
52W Low$0.78
Volume—
Avg Volume36.0K
Market Cap42.29M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,350.0% upside
Current
$1.04
$1.04
Target
$15.08
$15.08
$11.92
$15.08 avg
$19.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.42M | 17.19M | 14.45M |
| Net Income | 959.9K | 1.03M | 875.1K |
| Profit Margin | 5.2% | 6.0% | 6.1% |
| EBITDA | 1.74M | 1.49M | 1.43M |
| Free Cash Flow | 993.5K | 1.08M | 606.8K |
| Rev Growth | +1.0% | +13.6% | +14.7% |
| Debt/Equity | 0.15 | 0.16 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |